Showing 4231-4240 of 7542 results for "".
- BioPharmX: FDA Grants CARC Waiver; Post-Hoc Analysis for BPX-01 Completehttps://practicaldermatology.com/news/biopharmx-fda-grants-carc-waiver-post-hoc-analysis-for-bpx-01-complete/2457686/The FDA has waived its requirement for a dermal carcinogenicity study for BPX-01 from BioPharmX Corporation, eliminating several years of non-clinical research normally required for FDA review. BPX-01, a novel topical gel formulation of minocycline for the treatment of inflammatory
- Game On: Head-to-head Trials to Enhance Competition in PsO Markethttps://practicaldermatology.com/news/head-to-head-trials-to-enhance-competition-in-pso-market/2457684/An increase in head-to-head trials will enhance the competition within the psoriasis market, according to
- Trevi Therapeutics Appoints Yann Mazabraud as Chief Commercial Officerhttps://practicaldermatology.com/news/trevi-therapeutics-appoints-yann-mazabraud-as-chief-commercial-officer/2457685/Trevi Therapeutics, Inc. has named Yann Mazabraud as its Chief Commercial Officer and Head of International. Mr. Mazabraud will join Trevi’s senior management team and be responsible for overseeing Trevi’s commercial strategy and international operations.
- Colorescience Receives Patent for Even Up Clinical Pigment Corrector Formulationhttps://practicaldermatology.com/news/colorescience-receives-patent-for-even-up-clinical-pigment-corrector-formulation/2457687/The US Patent and Trademark Office (USPTO) has granted a patent for Colorescience’s LUMIRA™ formulation, a clinically tested, highly effective complex that addresses the appearance of skin discoloration, found in the 3-in-1 treatment product, Even Up® Clinical Pigment P
- Novartis Enters Licensing Deal for IL-17C Compound for Atopic Dermatitishttps://practicaldermatology.com/news/novartis-enters-licensing-deal-for-il-17c-compound-for-atopic-dermatitis/2457689/Novartis has entered into an exclusive license agreement with biotech companies Galapagos NV, Mechelen (Belgium) and MorphoSys AG, Planegg/Munich (Germany) to acquire the exclusive global development and marketing rights to MOR106 for atopic dermatitis and all other potential indications. Novarti
- Skin Cancer Foundation Accepting Grant Applicationshttps://practicaldermatology.com/news/skin-cancer-foundation-accepting-grant-applications/2457690/The Skin Cancer Foundation is now accepting applications for support of pilot research projects related to skin cancer. Two grants of $50,000 and one grant of $25,000 will be awa
- Save the Date: Skin Cancer Foundation's Champions for Change Gala this Octoberhttps://practicaldermatology.com/news/save-the-date-skin-cancer-foundations-champions-for-change-gala-this-october/2457692/The Skin Cancer Foundation’s signature fundraising event, the Champions for Change Gala, is coming October 25 in New York City. Robert J. Friedman, MD will be honored as the 2019 Champion for Change. The Skin Cancer Foun
- Cutera's New truSculpt iD Offers Personalized Body Sculptinghttps://practicaldermatology.com/news/cuteras-new-trusculpt-id-offers-personalized-body-sculpting/2457693/Cutera, Inc's new truSculpt® iD offers an evolution in body sculpting with unique hands-free capability and the ability to treat a full abdomen in as little as 15 minutes. truSculpt iD offers physicians and other qualified practitioners the flexibility to deliver personalized body sculpti
- New From Candela: Vbeam Primahttps://practicaldermatology.com/news/new-from-candela-vbeam-prima/2457694/Recently FDA-cleared, the Vbeam Prima from Candela offers two wavelengths to effectively treat a broad range of skin condi
- Cynosure Launches TempSure Vitalia for Feminine Wellnesshttps://practicaldermatology.com/news/cynosure-launches-tempsure-vitalia-for-feminine-wellness/2457696/Hologic's Cynosure division has launched TempSure™ Vitalia in North America. TempSure Vitalia is an FDA-cleared and Health Canada-approved advanced radiofrequency treatment that delivers therapeutic heat to internal